StockTipsArenaBeta

BUY Viyash Scientific Limited — Narendra Solanki, Anand Rathi

BUYViyash Scientific Limited

byNarendra Solanki, Anand RathiHorizon: NA (inferred 1 year)21 Aug 2026via CNBC Awaaz.

Entry₹266Inferred
Target₹310
Total upside +16.54%
Stop lossNot given
CMP₹257.6Just now
Active-3.16%+20.34%upside left 11 mo left
Follow Narendra Solanki for new callsGet alertsWatch VIYASH for new buy/sell callsGet alertsSee 1 other Long-term pick this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 14 Sept, 4:01 pm IST
10 supporting3 neutral0 opposing
Supports the BUY call (10)

Viyash Scientific Share Price Gains 7.19%, Most in Three Months

NewsGoogle News·19 Aug · 4w ago

(opens in new tab)

Viyash Scientific Publishes Q1 FY’27 Earnings Call Transcript for Investors

NewsGoogle News·16 Aug · 4w ago

(opens in new tab)

Viyash Scientific: Q1 FY’27 Revenue Surges 19.5% to ₹946 Cr, EBITDA Up 59%

NewsGoogle News·16 Aug · 4w ago

(opens in new tab)

Viyash Scientific Q1 FY27 Profit Surges 115% To Rs 79 Crore, Debt Halved

NewsGoogle News·16 Aug · 4w ago

(opens in new tab)
Neutral / worth noting (3)

Viyash Scientific Ltd provides an update on its proposed acquisition of BioForLife Italia S.r.l. The company has received the requisite approval from Italian authorities and revised the expected compl

BSE · Company Update·8 Sept · 5d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.